Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EBS, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Brincidofovir FDA approved Jun 2021 · Tembexa |
Smallpox | Phase 1 · NCT05935917 | Completed |
| Anti-Vector Antibody | Infections, Bacterial | Phase 4 · NCT02339155 | Completed |
| Vaccination with ACAM2000 | Smallpox Vaccine Adverse Reaction | Phase 4 · NCT02443623 | Completed |
| Sample Collection | Infections, Bacterial | Phase 4 · NCT02177721 | Not yet recruiting |
| Raxibacumab | Infections, Bacterial | Phase 4 · NCT02339155 | Completed |
| Hepatitis B Vaccine | Healthy Volunteers | Phase 3 · NCT01311674 | Terminated |
| BioThrax | Anthrax | Phase 3 · NCT03877926 | Completed |
| AV7909 | Anthrax | Phase 3 · NCT03877926 | Completed |
| Zanolimumab | T Cell Lymphoma | Phase 2/3 · NCT00877656 | Completed |
| ACAM2000 | Smallpox Vaccine Adverse Reaction | Phase 3 · NCT01158157 | Completed |
| DNA Damage-Inducible Transcript 3 Protei | T-cell Lymphoma | Phase 2 · NCT00893516 | Terminated |
| Dose of 1.1 x 10^10 CFU (Cohort 3) | Typhoid | Phase 2 · NCT00679172 | Completed |
| Dose of 5.0 x 10^9 CFU (Cohort 1) | Typhoid | Phase 2 · NCT00679172 | Completed |
| ACAM2000 Smallpox Vaccine | Smallpox | Phase 2 · NCT00053482 | Completed |
| Dose of 7.5 x 10^9 CFU (Cohort 2) | Typhoid | Phase 2 · NCT00679172 | Completed |
| Dose of of 1.7 x 10^10 CFU (Cohort 4) | Typhoid | Phase 2 · NCT00679172 | Completed |
Also used in these trials (approved or third-party drugs, not EBS's own candidates): Diphenhydramine Hydrochloride, Adjuvant, Ciprofloxacin, Doxycycline.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EBS holds $139.7M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EBS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EBS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →